Norwegian biotech company SoftOx Solutions AS (Euronext Growth Oslo:SOFTX) announced on Tuesday that the first patient has been recruited to SBE-01, the clinical study of its wound treatment agent.
The study team has now been able to screen and select several patients for the study, said Glenn Gundersen, chief medical officer of SoftOx.
SBE-01 is a first-in-human (phase I) study with the SoftOx's lead wound care product, SBE, which is designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to help develop the product into an effective infection-treatment solution in problematic, non-healing wounds.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA